- | TFF Pharmaceuticals
Advances Toward Dry-Powder Formulations for Monoclonal Antibodies
We designed the TFF method to eliminate that problem. The technology generates millimeter-sized droplets that, because of their large size, minimize protein exposure to air–liquid interfaces. Thus, we have observed far less denaturation
- | Selecta Biosciences
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon
Selecta Biosciences and Sobi have laid down a marker in their attempt to challenge Horizon for the gout market, delivering phase 3 data that suggest their SEL-212 candidate can match the efficacy of Krystexxa despite being administered less frequently.
- | Umoja Biopharma
5 reasons why collaboration is important in research
Meanwhile, David Fontana, chief operating officer (COO) at immuno-oncology company Umoja Biopharma, cited Umoja’s partnership with Lupagen as a good example of two companies leveraging each other’s resources, as well as expertise. Last year, the two companies announced a collaboration to evaluate extracorporeal in vivo delivery as a route of administration for Umoja’s VivoVec particles utilizing Lupagen’s Side CAR-T delivery system.
- | Elixirgen Therapeutics
A Next-Generation RNA Therapy Targets Telomere Disorders
Elixirgen is developing what it calls self-replicating RNA therapies to treat telomere biology disorders and other conditions.
- | Tessera Therapeutics
BoB@JPM: Gene Writing With Tessera’s Michael Severino, M.D.
Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it’s backed to pioneer a new category of genetic medicine it calls gene writing.
- | Aphaia Pharma
Steffen-Sebastian Bolz, CSO of Aphaia Pharma Shares Insights from the P-II Study for Chronic Weight Management in Individuals with Obesity
Aphaia continues to create additional bead formulations to broaden its product portfolio to potentially enhance treatment efficacy for other metabolic diseases and patient populations in the future.
- | Ashvattha Therapeutics
First patient enrolled in phase 1/2 study of hydroxyl dendrimer imaging agent
Ashvattha Therapeutics announced that the first patient has been enrolled in a phase 1/2 study to evaluate the ability of an imaging agent to cross the blood-brain barrier and target key markers of neuroinflammation.
- | Xalud Therapeutics
To Health: Xalud Therapeutics Is Bringing Gene Therapy to the Masses
When the term “gene therapy” comes up, the first thing that comes to mind is often some sort of gene replacement or gene editing (either a DNA correction or disruption) to treat a well-defined Mendelian genetic disorder like sickle cell disease or phenylketonuria—not some broad, genetic, complex condition like inflammation or osteoarthritis. Well, unless you are Diem Nguyen, PhD, CEO of Xalud Therapeutics in New York City.
